Aim: To study the effect of the duration of anti-tubercular treatment (ATT) on the recurrence of uveitis associated with latent tuberculosis (TB).
Methods: Retrospective review of all consecutive uveitis patients seen at a single, tertiary institution over 9 years with uveitis consistent with TB, positive tuberculin skin test with other causes ruled out, and a minimum of 6 months follow-up after completion of treatment. Clinical characteristics, treatment type, treatment duration and clinical response were recorded. Our main outcome measure was the effect of ATT duration on the recurrence of inflammation.
Results: Of the 182 eligible patients, 46 received ATT of ≥ 6 month's duration; 18 patients defaulted and received < 6 months treatment. The patients' mean age was 45.3 ± 13.2 years and most were female (n=118, 57.6%) and of Chinese race (n=104, 50.7%). Patients who completed > 9 months ATT were less likely to develop recurrence compared with those not treated with ATT (OR 0.09; 95% CI 0.01 to 0.76; p=0.027), while adjusting for potential confounders such as patient demographics, anatomical location of uveitis and corticosteroid therapy.
Conclusion: Patients with uveitis and latent TB treated with ATT of > 9 months duration had an 11-fold reduction in the likelihood of recurrence.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1136/bjophthalmol-2011-300209 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Recent advancements in the quest of benzazoles as anti-Mycobacterium tuberculosis agents.
Bioorg Chem
December 2024
Department of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER), Sector 67, S. A. S. Nagar, Punjab 160 062, India; School of Chemical Sciences, Indian Association for the Cultivation of Science, Jadavpur, Kolkata, West Bengal 700 032, India. Electronic address:
Tuberculosis (TB) remains a global health challenge, claiming numerous lives each year, despite recent advancements in drug discovery and treatment strategies. Current TB treatment typically involves long-duration chemotherapy regimens that are often accompanied by adverse effects. The introduction of new anti-TB drugs, such as Bedaquiline, Delamanid, and Pretomanid, offers hope for more effective treatment, although challenges persist keeping the quest to find new anti-TB chemotypes an incessant exercise of medicinal chemists.
View Article and Find Full Text PDFEthambutol-Induced Optic Neuritis and Vision Loss: A Case Report.
Cureus
July 2024
Pharmacology and Therapeutics, Government Medical College, Surat, Surat, IND.
Ethambutol is a first-line chemotherapeutic agent, which is commonly used in combination with other drugs for the treatment of tuberculosis. Ethambutol-induced optic neuritis is a serious and rare side effect that is either dose or duration-related and causes progressive painless vision loss, and cecocentral scotomas in the visual field. A rare case of ethambutol-induced optic neuritis was reported in a 52-year-old female who was taking anti-tubercular treatment for pulmonary tuberculosis for five months.
View Article and Find Full Text PDFClinical Features and Predictors of Treatment Outcome in Patients with Ocular Tuberculosis from the Netherlands and Indonesia: The OculaR TB in Low versus High Endemic Countries (ORTEC) Study.
Ocul Immunol Inflamm
May 2024
Department of Internal Medicine Section Allergy and Clinical Immunology, Erasmus University Medical Center, Rotterdam, The Netherlands.
Article Synopsis
- The study compares ocular tuberculosis (OTB) patients in the Netherlands, a low TB-endemic country, with those in Indonesia, a high TB-endemic country, focusing on clinical features, treatment approaches, and outcomes.
- Indonesian patients exhibited more severe symptoms and complications, such as higher rates of blindness and acute uveitis, while both groups had similar overall treatment success rates.
- Key predictors of poor treatment response included the presence of severe anterior chamber cells, specific types of eye lesions, and retinal vasculitis at the start of treatment.
A ten-year experience of musculoskeletal tuberculosis at a tertiary care hospital in South India.
J Orthop
October 2024
Department of Microbiology, Kasturba Medical College, Manipal, Manipal Academy of Higher Education, Karnataka, India.
Background: The delayed identification and management of musculoskeletal tuberculosis (MSTB) poses substantial health challenges and leads to significant morbidity. This study aimed to collate ten years of hospital data and provide valuable insights into the clinical, diagnostics, and outcomes of the patients diagnosed with MSTB.
Methods: A retrospective study was undertaken to review clinic records from 2013 to 2022 for all individuals diagnosed with MSTB in a tertiary care hospital in South India.
Kidney transplantation in patients on anti-tubercular therapy: A single centre observational study.
Transpl Infect Dis
June 2024
Department of Nephrology and Renal Transplant Medicine, Max Superspeciality Hospital, Saket, New Delhi, India.
Background: Tuberculosis (TB) is a common infection in chronic kidney disease. The prolonged therapy of TB can delay kidney transplantation in patients on antitubercular therapy (ATT).
Methods: This was a retrospective single-center study to analyze the safety of kidney transplantation and its outcomes in patients undergoing transplantation while on the continuation phase of ATT.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!